E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Primary Sjögren’s syndrome (PSS). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10040767 |
E.1.2 | Term | Sjogren's syndrome |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the extent to which rituximab improves symptoms of fatigue and oral dryness in patients with primary Sjögren's syndrome. |
|
E.2.2 | Secondary objectives of the trial |
SECONDARY OBJECTIVES To assess whether rituximab: •Increases salivary and lachrymal flow. •Produces improvement in serological and peripheral blood inflammatory features. •Improves quality of life and disease activity indices. •Is cost effective. •Produces improvement in systemic features. •To further validate questionnaires measuring disease activity and patient symptoms currently in development for use in the assessment of Sjögren’s Syndrome.
SUBSTUDY OBJECTIVES: •Central analysis to assess whether rituximab has a positive effect on glandular histology. •Central review of ultrasound imaging as an effective tool in determining treatment response
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Local and systemic T cell abnormalities in Primary Sjogren's Syndrome and their response to B cell depletion: • To compare peripheral blood T-cell transcriptional signatures in PSS patients with healthy and disease controls. • To compare peripheral blood T-cell transcriptional signatures in PSS patients pre- and post- B cell depletion • To characterise tissue distribution, phenotype, and gene expression of lesional T cells in PSS patients pre- and post-B-cell depletion.
|
|
E.3 | Principal inclusion criteria |
Eligibility waivers to inclusion/exclusion criteria are not permitted. 1. Aged between 18 and 80 years of age. 2. A confirmed diagnosis of primary Sjögren’s syndrome by AECG criteria (see Appendix B). 3. Positive for anti-Ro auto-antibodies. 4. Patients with a diagnosis of primary Sjögren’s syndrome (by AECG criteria) with more than 10 years disease duration must have at least one systemic feature of: • Hypergammaglobulinaemia (IgG over 16)*, or • Low complement C4*, or • Cryoglobulinaemia OR • Active/past history since diagnosis of the following (ascribed to Sjögren’s Syndrome): o purpura/cutaneous vasculitis, o lymphadenopathy, o persistent parotid salivary gland swelling not due to infection, o peripheral neuropathy (previously documented by nerve conduction tests), o interstitial lung disease confirmed by HRCT, o renal tubular acidosis requiring treatment, o CNS disease ascribed to Sjögren’s syndrome (confirmed by MRI), o myositis (CPK>2N and EMG or biopsy evidence of myositis), o inflammatory arthritis 5. An unstimulated salivary flow rate greater than 0ml in 15 minutes. 6. Symptomatic oral dryness (≥ 5/10 on patient-completed Likert**). 7. Symptomatic fatigue (≥ 5/10 on patient-completed Likert**). 8. Patients on corticosteroids, NSAIDS, antidepressants, DMARDs (e.g. methotrexate, hydroxychloroquine, azathioprine, MMF, leflunomide, ciclosporin etc.), or pilocarpine*** must have been on a stable dose for 4 weeks prior to receiving the first infusion of study medication and expected to remain on this dose throughout the study. If they have stopped any of these drugs they should have been off it for at least 4 weeks weeks prior to receiving study medication. 9. Given their written informed consent to participate in the trial and expected to be able to adhere to the study visit schedule and other protocol requirements.
*Anti-Ro antibody test, IgG, RF and C4 assays performed within 6 months of screening may be used to confirm eligibility. If greater than 6 months repeats should be performed locally at screening to confirm eligibility.
** LIKERT range 0-10 with 10 corresponding to worst severity.
*** Pilocarpine or drugs with similar pharmacological action should not be used within 12 hours of the assessment visits at screening, baseline, week 16, week 24, week 36 and week 48 (end of study).
|
|
E.4 | Principal exclusion criteria |
Patients will be excluded from the trial for the following reasons:
1. Diagnosis of secondary Sjögren’s syndrome. 2. Pregnancy, lactation or women of child-bearing potential (WCBP) unwilling to use medically approved contraception whilst receiving treatment and for 12 months after treatment has finished. 3. Men whose partners are of child-bearing potential but who are unwilling to use appropriate medically approved contraception whilst receiving treatment and for 12 months after treatment has finished. 4. Patient has active or prior hepatitis B or C, known HIV positivity or known history of tuberculosis. 5. Immunodeficiency or neutropaenia <1.5 x 109/l (unless a diagnosis of benign ethnic neutropaenia has been confirmed in which case the neutrophil count must be > 0.9 x 109/l at screening for Jamaican and Afro-Caribbean populations (60)). 6. Any AECG exclusion criteria not covered elsewhere (graft versus host disease, primary lymphoma excluding PSS, sarcoidosis). 7. Any malignancies that would normally preclude the use of rituximab within the past 5 years, including solid tumours, haematological malignancies and carcinoma in situ (except basal cell or squamous cell carcinoma of the skin that has been excised and cured) 8. Participation in a clinical study involving administration of an investigational drug within the past 4 weeks prior to the first infusion. 9. A history of major surgery within 3 months prior to first infusion or planned surgery during the study. 10. Receipt of live/attenuated vaccine within 4 weeks prior to the first infusion. 11. Previous exposure to rituximab or any other monoclonal antibody within the past 5 years. 12. History of recurring or chronic infections or underlying conditions which may further predispose patients to serious infection. 13. History of moderate to severe congestive heart failure according to the New York Heart Association (NYHA) functional classification system (see Appendix C) or other uncontrolled heart disease, or who have a clinically significant abnormal ECG at the time of screening. 14. History of receiving human/murine recombinant products or known allergy or anaphylactic reaction to a biologic agent or any component of the active substance or any of its excipients or murine components. 15. Patients with fibromyalgia or a diagnosis of significant depression or anxiety that in the opinion of the clinician would confound the interpretation of the study results. 16. Current or a history of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease (including demyelinating diseases such as multiple sclerosis). 17. Any history of organ transplant (with the exception of a corneal transplant >3 months prior to study entry). 18. Presence of a clinically significant illness or mental disorder within 4 weeks of the start of the trial where the safety of the individual might be at risk by entry into the trial, or where the individual does not have the capacity to consent or where the outcome of the therapy cannot be assessed by virtue of the illness or disorder. Each patient will be assessed individually and no person who wishes to participate will be unreasonably excluded by virtue of the illness or disorder.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure is the achievement of a 30% reduction at 48 weeks from baseline in either oral dryness or fatigue measured using patient-completed visual analogue scales (VAS - Range 0-100mm). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Evaluation at week 48 from baseline. |
|
E.5.2 | Secondary end point(s) |
Fatigue (VAS Score – Range 0-100mm) Oral Dryness (VAS Score – Range 0-100mm) Ocular Dryness (VAS Score – Range 0-100mm) Patient global assessments (VAS Score – Range 0-100mm) Physician global assessments (VAS Score – Range 0-100mm) Salivary Flow (Stimulated and Unstimulated Salivary flow) Lachrymal Flow (Schirmers I test of ocular function) Quality of Life - ESSPRI (EULAR Sjögren’s Syndrome Patient Reported Index) Quality of Life, Disease Damage and Disease Activity Indices (ESSDAI, SF-36, PROFAD-SSI) Serological and Peripheral Blood Inflammatory Features (Haematology biochemistry, serology and immunology assays) Incremental Cost-effectiveness Ratio (EQ-5D, Health Economics) Systemic disease activity features (SCAI, SSDAI, SSDDI, SSDI) Validity of questionnaires, assessments and disease indices Glandular Histology (Labial Gland Biopsy) Glandular composition (Salivary Gland Ultrasound Scan) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Evaluated at Baseline and weeks 16, 24, 36 and 48: Fatigue, Oral Dryness, Ocular Dryness, Patient global assessments, Physician global assessments, Salivary Flow, Lachrymal Flow, Quality of Life ESSPRI, Serological and Peripheral Blood Inflammatory Features (Haematology biochemistry, serology and immunology assays); Validity of questionnaires, assessments and disease indices
Evaluated at baseline, 24 and 48 Weeks: Quality of Life, Disease Damage and Disease Activity Indices (ESSDAI, SF-36, PROFAD-SSI); Incremental Cost-effectiveness Ratio (EQ-5D, Health Economics); Systemic disease activity features (SCAI, SSDAI, SSDDI, SSDI).
Evaluated from samples/scans performed at baseline, 16 and 36 weeks: Glandular Histology (Labial Gland Biopsy);Glandular composition (Salivary Gland US) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as the date of the last patient’s last treatment visit (week 26) plus 30 days. Long term follow up for purposes of the Main REC and Research Governance is to the last patient’s last trial follow up visit (week 48) which constitutes the non-interventional phase of the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 14 |